Navigation Links
Loss in Biological Technology

SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results

... income due to lower cash balances. Net loss decreased 26%, or $540,603 to $1.6 million for ... million for the same period in 2008 and the net loss for the six months ended June 30, 2009, decreased ... or $628,477 to $3.5 million, compared with a net loss of $4.1 million for the same period in 2008. ...

Novavax Reports Second Quarter 2009 Financial Results

... Inc. (Nasdaq: NVAX ) today reported a net loss of $8.5 million, or $0.10 per share, for the second quarter of 2009 compared to a net loss of $9.4 million, or $0.15 per share, for the ... ended June 30, 2009, Novavax reported a net loss of $16.9 million, or $0.22 per share, as compared ...

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

... ended June 30, 2009, the Company reported a net loss of $1,761,887, or $0.13 per basic and diluted share, compared to a net loss of $2,377,440, or $0.19 per basic and diluted ... ended June 30, 2009, the Company reported a net loss of $4,793,088, or ...

NeurogesX Reports Second Quarter 2009 Results

... the United States and European Union. Net loss for the second quarter of 2009 was approximately $5.4 million, compared to a net loss of approximately $6.9 million for the second quarter of 2008. Net loss per share attributable to common stockholders was ...

AutoImmune Inc. Reports 2009 Second Quarter Financial Results

... (OTC Bulletin Board: AIMM) today reported a net loss of $86,000, or $0.01 per share basic and diluted, ... months ended June 30, 2009, compared with a net loss of $86,000, or $0.01 per share basic and diluted, ... For the six months ended June 30, 2009, the net loss was $256,000, or $0.02 per share basic and ...

Microbix Sales Grow 22% For Nine Months

... ended June 30, 2009, the Company recorded a net loss of $672,366 or one cent a share compared to a loss of $945,111 or three cents a share in the same ... $ 1,079,492 in the same period in 2008. A lower loss for the third quarter compared to 2008 reflected ...

GenVec Reports Second Quarter 2009 Financial Results

... ) GenVec reported a net loss of $4.8 million ($0.05 per share) for the three months ended June 30, 2009 compared to a net loss of $6.6 million ($0.08 per share) in the ... the six months ended June 30, 2009, GenVec's net loss was $10.5 million ($0.12 per share), compared to ...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... ended June 30, 2009. InterMune reported a net loss for the second quarter of 2009 of $36.7 million, or $0.81 per share, compared with a net loss of $29.6 million, or $0.76 per share, in the ... of pirfenidone. InterMune recorded a loss on extinguishment of debt of $9.5 million, of ...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

... expense related to FAS123(R). Net loss for the second quarter of 2009 was $20.2 million, ... 2008. The number of shares used to calculate net loss per share was 61,137,755 for this period versus ... expense related to FAS123(R). Net loss for the first six months of 2009 was $37.7 ...

OncoGenex Reports Second Quarter 2009 Financial Results

... results of OncoGenex thereafter. The loss attributable to common shareholders for the ... 2008. For the six months ended June 30, 2009 the loss attributable to common shareholders increased to ... ------------------ ------------------ loss for the period before taxes 4,557 1,967 ...

Telik Announces Second Quarter 2009 Financial Results

... Inc. (Nasdaq: TELK ) today reported a net loss of $5.7 million, or $0.11 per share, for the ... quarter ended June 30, 2009, compared with a net loss of $13.6 million, or $0.26 per share, for the ... months ended June 30, 2009, Telik reported a net loss of $13.4 million, or $0.25 per share, compared ...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... costs were $19.0 million. - GAAP net loss and net loss per share for the quarter were ($11.9) ... and ($0.14), respectively. - Adjusted net loss and adjusted ...

Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval

... of CTI's Bresso, Italy research facility. Net loss attributable to common shareholders decreased by ... million ($0.06 per share), compared to a net loss attributable to common shareholders of $59.3 ... for the same period in 2008. The reduction in net loss per share is due to an increase in the number of ...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

... or $0.29 per diluted share, compared to a net loss of $7.7 million, or $0.17 per share, for the ... or $0.30 per diluted share, compared to a net loss of $42.2 million, or $0.96 per share, for the ... 14,132 (7,689) 14,583 (42,144) loss from discontinued operations ...

PDI Reports 2009 Second Quarter Financial Results

... million benefit in 2009 due to a reduction in the loss contract accrual associated with the mutual ... in 2009 compared to 2008. Total operating loss for the second quarter of 2009 was $4.7 million ... to $7.9 million in the same period of 2008. Net loss per share for the second quarter of 2009 was ...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

... Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.60 per ... & Notes On a reported basis, the net loss attributable to common stockholders for the three ... same period in 2008. On a non-GAAP basis, the net loss for the three months ended June 30, 2009, was ....

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

... ended June 30, 2009, Cadence reported a net loss of $8.3 million, or $0.17 per share, compared to a net loss of $15.6 million, or $0.41 per share, for the ... ended June 30, 2009, Cadence reported a net loss of $18.7 million, or $0.40 per share, compared to ...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... in Q2 2009 was $35 million, compared to a loss of $67 million in 2008. - Non GAAP diluted ... for INTUNIV. The US GAAP operating loss from continuing operations in Q2 2008 included ... loss). Discontinued operations The loss from discontinued operations for the three months ...

Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results

... ended June 30, 2009. Optimer reported a net loss for the second quarter of 2009 of $12.4 million, ... Company's expectations. This compares to a net loss for the second quarter of 2008 of $8.1 million, or $0.29 per share. The increase in net loss was primarily due to higher research and ...

NxStage Reports Second Quarter 2009 Financial Results

... percent in the second quarter of 2008. Net loss for the second quarter of 2009 was $12.5 million, ... facility, recorded as interest expense, the net loss for the second quarter of 2009 was better than the Company's second quarter guidance for a net loss of $11.5 to $12.5 million. This compares to a ...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

... Financial Results The Company reported a net loss of $9.7 million ($0.28 diluted loss per share on a loss applicable to common shares of $9.8 million) for ...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

... in the second quarter of 2008. Net loss decreased to $3.9 million in the second quarter ... the second quarter of 2008. Basic and diluted net loss per share was $0.14 in the second quarter of 2009, compared with basic and diluted net loss per share of $0.15 in the second quarter of 2008. ...

SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS

... the second quarter financial results for net loss and cash utilization were in-line with the ... expenses and travel expenses. The net loss for the second quarter of 2009 was $0.26 per share, compared to a net loss of $0.25 per share for the second quarter of ....

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... of 2009 and 2008, respectively. The net loss was $6.5 million for the second quarter of 2009, compared to a net loss of $7.1 million for the second quarter of 2008. Included in the net loss for the second quarter of 2009 is a $0.4 million ...

Caliper Life Sciences Reports Second Quarter 2009 Results

... 3%, respectively. The Company narrowed its net loss to $4.1 million ($0.08 per share) in the second quarter of 2009, from a net loss of $6.7 million ($0.14 per share) in the same ... as of June 30, 2009. Reduced adjusted net loss per share to $0.05 per share compared to $0.09 ...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

... and six months ended June 30, 2009, compared to a loss per share of $0.05 and $1.52 in the same prior ... the six months ended June 30, 2009, compared to a loss from operations of $297.5 million in the same ... 80,753 132,853 164,599 Impairment loss on goodwill - ...

Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results

... Inc. CONSOLIDATED STATEMENTS OF loss AND COMPREHENSIVE LOSS ... loss before the following: 4,338,489 ... - - - loss on sale of Transition Therapeutics Inc. ...

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

... 30, 2009, Sangamo reported a consolidated net loss of $4.5 million, or $0.11 per share, compared to a consolidated net loss of $7.4 million, or $0.18 per share, for the same ... months ended June 30, 2009, the consolidated net loss was $11.3 million, or $0.28 per share, compared ...

Neurocrine Biosciences Reports Second Quarter 2009 Results

... quarter of 2009, the Company reported a net loss of $15.3 million, or $0.39 per share, compared with a net loss of $21.0 million, or $0.55 per share, for the ... ended June 30, 2009, the Company reported a net loss of $34.9 million, or $0.90 per share, as compared ...

Sunesis Reports Financial Results for the Second Quarter 2009

... quarter of 2009 was $3.5 million, with a net loss of $22.9 million, including non-cash charges of ... related to the financing completed in April. loss from operations was $1.9 million for the second ... ---------- ---------- ---------- loss from operations (1,931,620) ...

Cynosure Reports Second Quarter 2009 Financial Results

... sales prices. Cynosure reported a net loss for the second quarter of 2009 of $2.3 million, ... share, in the second quarter of 2008, and a net loss of $4.0 million, or $0.32 per basic and diluted ... with 66.8% for the same period in 2008. Net loss for the first half of 2009 was $6.3 million, or ...

Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results

... the second quarter of 2008. Idenix reported a net loss of $16.3 million, or a loss of $0.28 per basic and diluted share, for the second quarter ended June 30, 2009, compared to a net loss of $18.9 million, or ...

BioMS Medical announces second quarter 2009 results

... $0.02 per share compared with a consolidated net loss of ($0.4) million or ($0.00) per share for the ... $0.00 per share compared with a consolidated net loss of ($7.1) million or ($0.08) per share for the ... 85 43 42 31 loss on disposal of property and ...

Vasogen Announces Second Quarter 2009 Results

... acquired, dissolved, or liquidated. The net loss for the second quarter of 2009 was $1.4 million, or $0.06 per common share, compared with a net loss of $7.4 million, or $0.33 per common share for the same period in 2008. The $1.4 million loss for the three months ended May 31, 2009 included ...

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

... period 1 January to 30 June 2009. - The loss after tax realised in the 2nd quarter of 2009 ... Statement (1 January - 30 June 2009) The loss after tax realised in the 2nd quarter of 2008 was ... to 29,8m DKK (4,0m EUR) in 2008. The accumulated loss after tax for the first half of 2009 was 34,5m ...

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

... doses, experienced significantly more weight loss on average (11%; 22 pounds, p<0.01) than those ... role of leptin in regulating body fat, the weight loss in these patients was predominantly due to a ... combination arms achieved more weight loss than placebo. The magnitude of ...

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August

... osteoporosis and prevention and treatment of bone loss in patients undergoing hormone ablation for ... breast cancer who are at increased risk for bone loss and consequently fracture. We look forward to ... women, and treatment and prevention of bone loss in patients undergoing hormone ablation for ...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

... to the same period in the previous year loss for the period The Company recorded a loss of $4,134,000 and $10,707,000 respectively, for ... nine month periods ended April 30, 2009, for a loss per common share of $0.08 and $0.21, ....

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

... previously reported results on the primary weight loss endpoints and measures of cardiometabolic risk. ... show that Contrave initiates and sustains weight loss and can improve predictive markers for heart ... The trial evaluated the additional weight loss of Contrave (32mg naltrexone SR/360mg bupropion ...

Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting

... Previous studies have shown significant weight loss with Qnexa treatment. Both podium presentations will highlight the benefit of weight loss and the corresponding positive impact on type 2 ... phase 3 EQUATE trial (OB-301) shows that weight loss with Qnexa stops the progression of type 2 ...
Other Contents
(Date:9/19/2014)... of Oklahoma biology professor will study the unique bioelectric ... could eventually benefit people,s health. The OU researcher ... energy required to produce the signals used to map ... signals at a rate of 500-600 discharges a second ... the electric fish are extreme, but necessary for survival. ...
(Date:9/19/2014)... , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... company focused on the growing m-commerce market, updates the "Wocket in ... in the lightweight and light middleweight weight classes, Vinny Pazienza ... was announced that Game of Thrones actor Ciaran ... with Children star Katey Sagal have been cast ...
(Date:9/18/2014)... sleep-promoting circuit located deep in the primitive brainstem has ... researchers at Harvard School of Medicine and the University ... is only the second "sleep node" identified in the ... and sufficient to produce deep sleep. , Published online ... demonstrates that fully half of all of the brain,s ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2
(Date:9/22/2014)... Austin, Texas (PRWEB) September 22, 2014 ... testing and treatment, will work with companies to help ... prevent the development of diabetes as part of a ... Stop Diabetes @ Work initiative. , PreDiabetes Centers ... Texas Department of Transportation in Austin on Tuesday, October ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... that bacterial pneumonia can raise your risk of heart problems, ... and kill heart cells, increasing the chances of heart failure, ... report. In mice, monkeys and human heart tissue, researchers ... and they tried a vaccine that might one day prevent ...
(Date:9/22/2014)... At the 10th Clinton Global ... Partnership (SNP) announced the successful launch of a ... Risk Reduction Program for Women. The announcement of ... their risk of heart disease through a seafood-rich ... for addressing significant global challenges made by CGI ...
(Date:9/22/2014)... Burbank, CA (PRWEB) September 22, 2014 ... social and mobile recruiting, announced today an ... talent management solutions for the healthcare industry. ... to TweetMyJobs’ suite of social recruiting solutions ... management software designed specifically for healthcare organizations. ...
(Date:9/22/2014)... -- In a collaboration that will encompass a ... and patient care and accelerate personalized genomic medicine, ... Medical Center (BIDMC) have established a new academic, ... today. , A recently signed agreement calls for ... a comprehensive relationship in the areas of research ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3
Other TagsOther Tags